A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) infection can cause life-threatening pneumonia and bronchiolitis, posing a significant threat to human health worldwide, especially children the elderly. Currently, there is no specific treatment for RSV infection. The most effective measures preventing are vaccines prophylactic medications. However, not all population groups eligible approved or antibody-based preventive Therefore, an urgent need develop novel drugs available people of ages. High-throughput assays that evaluate efficacy viral entry inhibitors vaccine-induced neutralizing antibodies in blocking crucial evaluating vaccine drug candidates. We developed efficient assay using lentiviral pseudovirus carrying fusion (F) protein type A B RSV. In addition, essential parameters were systematically optimized, including number transfected plasmids, storage conditions pseudovirus, cell types, numbers, inoculum, time point detection. Furthermore, convalescent sera exhibited comparable inhibitory activity this as authentic neutralization assay. established robust pseudovirus-based RSV, which holds excellent promise studying mechanisms, inhibitors, assessing vaccine-elicited against